TITLE

Next Generation Sequencing-Based Investigation of Potential Patient-to-Patient Hepatitis C Virus Transmission during Hemodialytic Treatment

AUTHOR(S)
Zhao, Qi; Wen, Yujie; Jiang, Yan; Zhang, Chen; Li, Yang; Zhang, Guiyun; Zhang, Lei; Qiu, Maofeng
PUB. DATE
January 2016
SOURCE
PLoS ONE;1/25/2016, Vol. 11 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We investigated potential patient-to-patient transmission of hepatitis C virus (HCV) in two hemodialysis centers in Beijing, China. Approximately 8.25% (32/388) hemodialysis patients were HCV antibody positive, and 4.90% (19/388) were HCV RNA-positive, which consisted of 2a genotype (1/19) and 1b genotypes (18/19). Using next generation sequencing (NGS) approach, MiSeq platform, we sequenced HCV, targeting hypervariable region 1 (263 base-pairs) of genotype 1b specimens and obtained 18 to 243 unique HCV variants. Analysis of phylogenetic tree, viral epidemiology signature pattern (VESP) and Shannon entropy indicated no obvious HCV similarity for most HCV infections but limited HCV variants from Patient 31 (P31) were closer with respect to evolutionary relationship with Patient 24 (P24). However, it was unlikely that HCV was transmitted directly from P24 to P31 in the hemodialysis center. Otherwise, their genetic distance (3.92%-8.92%), would have been much less. Moreover, P31 was infected less than two years before specimen collection, and other external high risk factors existed for these two patients. Thus, our data indicated no evidence of patient-to-patient transmission of HCV in the two hemodialysis centers, suggesting that current HCV infection control measures are effective.
ACCESSION #
112476766

 

Related Articles

  • Mahajan R et al. (Clin Infect Dis 2014; 58: 1055–61).  // Clinical Infectious Diseases;Jun2014, Vol. 58 Issue 12, p1792 

    A correction to the article "Mortality Among Persons in Care with Hepatitis C Virus Infection: The Chronic Hepatitis Cohort Study (CHeCS)" in a 2014 issue.

  • Enhancing Assessment and Treatment of Hepatitis C in the Custodial Setting. Post, Jeffrey J.; Arain, Amber; Lloyd, Andrew R. // Clinical Infectious Diseases;Aug2013, Vol. 57 Issue Supp 2, pS70 

    Acute and chronic hepatitis C (HCV) infections are prevalent in custodial settings worldwide, yet provision of antiviral therapies is uncommon. This disparity between the burden of disease and hepatitis service delivery reflects the marginalized patient population, which features high rates of...

  • Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Badri, Prajakta; King, Jennifer; Polepally, Akshanth; McGovern, Barbara; Dutta, Sandeep; Menon, Rajeev; Badri, Prajakta S; King, Jennifer R; Polepally, Akshanth R; McGovern, Barbara H; Menon, Rajeev M // Clinical Pharmacokinetics;Mar2016, Vol. 55 Issue 3, p275 

    The development of direct-acting antiviral (DAA) agents has reinvigorated the treatment of hepatitis C virus infection. The availability of multiple DAA agents and drug combinations has enabled the transition to interferon-free therapy that is applicable to a broad range of patients. However,...

  • A Quick Cure for the 'Tattoo Flu'.  // Men's Fitness;Jan2002, Vol. 18 Issue 1, p50 

    Discusses a study which examined the use of interferon alpha-2b in treating hepatitis C virus (HCV) infection. Transmission of HCV; Prevalence of HCV infection in the U.S.; Activities at high-risk for HCV.

  • The Comparision of Hepatitis C Virus (HCV) Core Antigen and HCV RNA Levels for Diagnosis of HCV Infection in Haemodialysis Patients. Kizilates, Filiz; Cekin, Yesim; Sari, Funda; Sarikaya, Metin; Seyman, Derya; Oztoprak, Nefise; Cetinkaya, Ramazan // HealthMed;2013, Vol. 7 Issue 8, p2395 

    The diagnosis and monitoring of HCV infection are commonly based on anti-HCV assays. But anti-HCV assays indicate only the exposure of virus therefore confirmation with nucleic acid amplification assays is supposed. Architect HCV Ag assay is recently developed for detecting HCV nucleocapsid...

  • Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. Robaeys, Geert; Grebely, Jason; Mauss, Stefan; Bruggmann, Philip; Moussalli, Joseph; De Gottardi, Andrea; Swan, Tracy; Arain, Amber; Kautz, Achim; Stöver, Heino; Wedemeyer, Heiner; Schaefer, Martin; Taylor, Lynn; Backmund, Markus; Dalgard, Olav; Prins, Maria; Dore, Gregory J. // Clinical Infectious Diseases;Aug2013, Vol. 57 Issue Supp 2, pS129 

    In the developed world, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). The burden of HCV-related liver disease in this group is increasing, but treatment uptake among PWID remains low. Among PWID, there are a number of barriers to...

  • The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Durham, David P.; Skrip, Laura A.; Bruce, Robert Douglas; Vilarinho, Silvia; Elbasha, Elamin H.; Galvani, Alison P.; Townsend, Jeffrey P. // Clinical Infectious Diseases;2/1/2016, Vol. 62 Issue 3, p298 

    Background. The effectiveness of interferon-free direct-acting antivirals (DAA) in treating chronic hepatitis C virus (HCV) is limited by low screening and treatment rates, particularly among people who inject drugs (PWIDs). Methods. To evaluate the levels of screening and treatment with...

  • Hepatitis C Transmission and Treatment in Contact Networks of People Who Inject Drugs. Rolls, David A.; Sacks-Davis, Rachel; Jenkinson, Rebecca; McBryde, Emma; Pattison, Philippa; Robins, Garry; Hellard, Margaret // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Hepatitis C virus (HCV) chronically infects over 180 million people worldwide, with over 350,000 estimated deaths attributed yearly to HCV-related liver diseases. It disproportionally affects people who inject drugs (PWID). Currently there is no preventative vaccine and interventions feature...

  • AlphaIFN Clearance Reduced in HD Patients.  // Kidney;Jul/Aug99, Vol. 8 Issue 4, p173 

    Studies the pharmacokinetics of alpha-interferon-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function. Mean maximum serum alpha-interferon concentration; Quantification of the impact of renal failure on alpha-interferon pharmacokinetics.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics